CARDIOLOGY INSIGHTS
A Quiet Signal Worth Taking Seriously
Understanding Fatty Liver Disease Before It Becomes Something More
SONAL CHANDRA, MD
Fatty liver is one of the clearest quiet signals your metabolism can send; often years before you feel anything wrong. There are typically no early symptoms, yet it has become the most common liver condition in the developed world, affecting an estimated one in four adults globally. What makes it clinically important is not just what it means for the liver, but what it can reveal about cardiometabolic risk that affects the heart and arteries.
What Fatty Liver Disease Actually Is
MASLD — A New Name for a Familiar Problem
What was long called non-alcoholic fatty liver disease (NAFLD) has been renamed metabolic dysfunction-associated steatotic liver disease, or MASLD, reflecting a clearer understanding that this condition is rooted in metabolic dysfunction comprising of insulin resistance, dyslipidemia, visceral adiposity — rather than simply the absence of alcohol use.
In its early form, fat accumulates in liver cells without significant inflammation. In more advanced stages, inflammation sets in (metabolic steatohepatitis, or MASH), followed potentially by fibrosis, cirrhosis, and liver failure. But the path from stage to stage is not inevitable, and reversal is genuinely possible, particularly in the earlier phases.
The Metabolic Connection
MASLD does not occur in isolation. It clusters powerfully with type 2 diabetes, hypertension, elevated triglycerides, and low HDL: the components of metabolic syndrome. Insulin resistance is thought to be the central driver, pushing excess fat into the liver when it cannot be adequately processed elsewhere.
​
Prediabetes deserves particular attention in this context. Many patients with MASLD are not yet diabetic but are living in a prolonged state of insulin resistance whereby a condition in which the body’s cells respond poorly to insulin signals, causing the pancreas to compensate by producing more. This excess insulin drives fat storage in the liver, promotes inflammation, and quietly advances metabolic dysfunction years before a diabetes diagnosis is made. Blood sugar in the prediabetic range is not a benign waiting room. It is an active metabolic state that warrants the same urgency as established disease.
​
Improving insulin sensitivity, which is the body’s ability to respond appropriately to insulin, is one of the most direct levers available for reversing early fatty liver disease. Strategies that reduce visceral fat, improve muscle glucose uptake, and lower fasting insulin levels address the disease at its metabolic root. Weight loss, aerobic exercise, reduction of refined carbohydrates, and improved sleep quality all contribute meaningfully to insulin sensitivity. When these measures are implemented together, their effect on hepatic fat can be significant and measurable within months.
Why Cardiologists Pay Close Attention
The cardiovascular implications of fatty liver disease are not incidental. Studies consistently show that people with MASLD carry a significantly elevated risk of cardiovascular events independent of traditional risk factors.
The liver's metabolic dysfunction contributes to atherogenic dyslipidemia (elevated small, dense LDL and triglycerides with suppressed HDL), systemic inflammation, and impaired glucose regulation, all of which together accelerate atherosclerosis.
In clinical practice, the finding of fatty liver on imaging should prompt a full cardiovascular risk assessment
What Moves the Needle
Lifestyle: The Most Powerful Tool Available
The evidence here is unambiguous. A sustained reduction of five to ten percent of body weight produces measurable improvement in liver fat; greater reductions can resolve inflammation and begin to reverse early fibrosis. Mediterranean-pattern eating with emphasis on olive oil, vegetables, legumes, fish, and whole grains has particular evidence in this context.
Structured aerobic exercise reduces hepatic fat content even in the absence of weight loss. These are not consolation interventions but rather primary treatment.
Emerging Pharmacology
A class of medications that works in part by improving insulin sensitivity and reducing appetite has shown meaningful promise in reducing liver fat and hepatic inflammation in clinical studies. These agents, which also carry cardiovascular benefits, are an active area of research and an increasingly relevant option for patients with MASLD who have not achieved sufficient response through lifestyle measures alone.
​
The pharmacologic landscape in this space is evolving. If you were told you had fatty liver disease some time ago and have not revisited the conversation recently, it is worth doing so, the options now being discussed are different from what was available even a few years ago.
What You Should Know and Ask
Fatty liver disease has an unusual quality among serious medical conditions: it is both common and consistently underacted upon. It appears as an incidental finding on abdominal ultrasounds ordered to evaluate gallstones. It surfaces on CT scans as an incidental finding when investigating an unrelated complaint. It shows up on MRI studies ordered for entirely different structures. A radiologist notes it in a single line. The ordering physician, focused on the original question, moves on. The patient is never told or is told in passing, without context or follow-up plan.
​
If fatty liver disease has been noted anywhere in your medical records even as a passing comment in a radiology report from years ago, it deserves active follow-up. Not watchful waiting. Not a note filed and forgotten. A full metabolic workup, assessment of insulin resistance, cardiovascular risk stratification, and a structured conversation about lifestyle and, where appropriate, medical treatment are the right response. The condition noted incidentally is the same condition that, left unaddressed, can progress to fibrosis, cirrhosis, and cardiovascular disease over years.
Fatty liver disease is not a bystander condition. It is a window into the metabolic environment your heart and arteries are living in.